Am J Health Syst Pharm. 2005;62(21):2260-2264. Verify that the patient is receiving some source of exogenous glucose before initiating infusion (e.g., total parenteral nutrition [TPN], i.v. fluids ...

Infusion pumps, glucose monitors, insulin pumps and dental implants were among the products with delayed side effect reporting TUESDAY, March 18, 2025 (HealthDay News) -- Other people could be having ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

The assay results were the same for dilute treprostinil solutions in 5% dextrose injection at concentrations of 0.02 and 0.13 mg/mL. The pH values for these solutions remained within acceptable ...

Semaglutide is already available in Ireland through diabetes medication Ozempic. However, its producer Novo Nordisk uses the ...

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

GUANGDONG, China and BAGSVAERD, Denmark I March 24, 2025 IThe United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

BD, Medtronic and Abbott were among the top 10 device companies with the highest number of late reports to the FDA, the study ...